Clinical Trial Update: Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study evaluating RMC-6236 in patients with advanced solid tumors harboring RAS mutations, including non-small cell lung cancer and colorectal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• RMC-6236

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1, Phase 2 | Status: RECRUITING